Novartis CEO Vas Narasimhan states that Europe requireds a “complete reconsider” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed.
With his comments on Tuesday, Narasimhan echoed calls from leaders of other European drugcreaters—such as Roche and AstraZeneca—who have been critical of Europe’s healthcare policies which they state hinder innovation.
Last week, Roche CEO Thomas Schinecker referred to Europe’s bureaucracy and over-regulation as “mind-blowing” and warned that the continent was falling further behind the United States and China as an indusattempt innovator.
The criticisms come after the indusattempt’s top companies—including Novartis, Roche and AstraZeneca—have created most-favored-nation (MFN) pricing deals with the U.S. and with President Donald Trump inquireing other wealthy nations to pay their “fair share” for medicines.
Earlier this month, Germany unveiled a reform package that would cut healthcare costs by billions and would trigger discounts on branded medicines.
“We’ve been large investors in Germany for decades and I would state more broadly, the pharmaceutical indusattempt is one of the largest employers and sources of innovation in Europe,” Narasimhan informed reporters during a Tuesday conference call as Novartis revealed its first-quarter financials. “Policies like this sfinish the wrong signal to a high innovation indusattempt like ours, where we see U.S. and China actively investing in the biotech ecosystem to create it highly competitive.”
On the flip side, the U.S. recently formed a partnership with the U.K. which will free it from tariffs on pharmaceutical products exported to America in exalter for the U.K. increasing its spfinishing for novel drugs by 25%.
Backing up Narasimhan’s warning that there could be a delay in access to new medicines in Europe is a recent report from GlobalData, which displayed that since Trump laid out his MFN plan in May of last year, new drug launches in Europe have declined by 35%.
“We are engaging with governments across Europe as well as in Japan, to hopefully receive to a better place. I consider we’re not seeing the progress that we had hoped to see at the pace that we had hoped to see, so I consider there has to be some urgency here,” Narasimhan stated. “I do expect across the indusattempt, there will be difficult decisions companies will have to create in terms of how they launch or ultimately progress.”
Since Trump’s MFN pricing scheme is tied to what other wealthy countries pay for their drugs, it is imperative for other countries in Europe to increase their healthcare spfinishing, Narasimhan stated.
“What’s very important now is that we continue to advocate for the European government to ensure they’re properly rewarding innovation and not take policies that really don’t enable companies like ours to continue to invest in Europe, in clinical trials, in manufacturing,” Narasimhan stated. “Europe requireds a healthy ecosystem, which is going to require a complete reconsider on how reimbursement systems work in the continent.”
Leave a Reply